Activation of the insulin-like growth factor 1 receptor (IGF1R) signaling pathway contributes to EGFR-TKI resistance in NSCLC patients, and the IGF1R pathway might be a promising target for overcoming resistance [72]. This evidence concerns the gene IGF1R and non-small cell lung carcinoma.